Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KCT-0809 in Dry Eye Syndromes
NCT01211951Phase 2Completed
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ozagrel in dry eye disease (DED) (4 arms), sponsored by Kissei Pharmaceutical Co., Ltd. Primary endpoint: Corneal-conjunctival staining scores at 4 weeks. Status: completed.
02
Drugs
ozagrel
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT01211951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01211951.